Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
14 Jun 2022 | 03:35 pm |
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.
The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.
Key Contacts
Latest press releases
Show me all press releasesPinsent Masons advises Poundland on major restructuring plan
Multinational law firm Pinsent Masons has advised the board of Poundland Limited in relation to its restructuring plan (sanctioned by the High Court on 26 August 2025) and related financing arrangements.
Pinsent Masons hires leading funds partner in Luxembourg
Multinational law firm Pinsent Masons has today announced the hire of Manfred Dietrich to lead its funds and asset management team in Luxembourg.
Pinsent Masons adds leading energy partner in Australia
Multinational law firm Pinsent Masons continues to build on its strong energy sector expertise with the appointment of Nick Li as a partner in its corporate team in Melbourne.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons announces FY24/25 results
Multinational law firm Pinsent Masons has today unveiled its unaudited financial results for the year ending 30 April 2025. This year's results have delivered a revenue increase of 4.7% after a year of continued growth within the firm’s core sectors and across its jurisdictions.
Pinsent Masons announces new leadership for Global IP Group and Life Sciences
Pinsent Masons has appointed Judith Krens (Partner, Amsterdam) and Tom Nener (Partner, Birmingham) as co-leads of the Global Intellectual Property (IP) team, and has appointed Charlotte Weekes (Partner, London) as Head of Life Sciences. The appointments come in light of the upcoming departure of Clare Tunstall, the current Head of IP and Life Sciences, who will be leaving the firm in the Autumn.
Pinsent Masons hires senior litigation and investigations partner Melanie Ryan in London
Multinational law firm Pinsent Masons has appointed litigation partner Melanie Ryan to join its Global Investigations team in London.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]